Rate of major bleeding with ibrutinib versus bendamustine-rituximab in chronic lymphocytic leukemia: A population-based cohort study was written by Dhopeshwarkar, Neil;Yang, Wei;Hennessy, Sean;Rhodes, Joanna M.;Cuker, Adam;Leonard, Charles E.. And the article was included in American Journal of Hematology in 2022.Synthetic Route of C16H21Cl2N3O2 The following contents are mentioned in the article:
The approval of ibrutinib, a Bruton’s Tyrosine Kinase (BTK) inhibitor, has revolutionized the treatment landscape for treatment-naive and relapsed or refractory chronic lymphocytic leukemia (CLL) patients. However, bleeding was frequently observed in ibrutinib-treated patients and has become a notable safety concern. Major bleeding, however, was uncommonly observed in clin. trials, with incidences ranging from 2%-8%. Herein authors compare incidence rates of real-world major and clin.-relevant bleeding between ibrutinib- and bendamustine-rituximab (BR)-treated individuals diagnosed with CLL. The primary outcome was major bleeding, defined as bleeding resulting in inpatient hospitalization. The secondary outcome was clin.-relevant bleeding, which was a composite of bleeding events resulting in inpatient hospitalization (i.e., major bleeding) and those resulting in emergency department presentation. This study found that, though the rate of major bleeding with ibrutinib in a real-world population was comparable to clin. trial populations, an increased rate of clin.-relevant bleeding compared to BR is evident. As the use of 2nd-generation BTK inhibitors increases, clinicians will require information on the real-world risks with individual agents within the therapy class. This study will help serve as a benchmark for ibrutinib-related bleeding until such post-market studies among all available BTK inhibitors can be conducted. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Synthetic Route of C16H21Cl2N3O2).
4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Imidazole is a heterocyclic compound with a five-membered planar ring. It is amphoteric and highly polar. The pharmacophore of imidazole exists in bioactive compounds including amino acids, plant growth regulators and therapeutic agents.n increase of the alkyl chain length of the alcohols. Synthetic Route of C16H21Cl2N3O2
Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem